NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

NovaBridge BiosciencesNASDAQ: NBP

Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025

Cost of revenue remains negative

Q4 FY2025 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0.

Context

  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2025
$0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

Mixed currencies · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How NBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
NBP Competitors
Cost of Revenue for NBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALTAltimmune, Inc.LTM Mar 2026$14.98M USD——41619.4%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$2.15M USD-8.3%——
ANNXAnnexon, Inc.LTM Mar 2026$1.9M USD———
AURAAura Biosciences, Inc.LTM Mar 2026$574K USD+97.3%——
ENGNenGene Holdings Inc.LTM Apr 2026$369K USD———
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$82K USD———
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY———
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$0 USD—+8.0%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%+10.1%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 USD———
GALTGalectin Therapeutics Inc.LTM Mar 2026$0 USD———
Peer median (excluding NBP) —-8.3%+9.0%41619.4%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Revenue88.03M(10.7M)4.49M00
Cost of Revenue46.43M0000
Gross Profit41.59M(10.7M)4.49M00
Gross Margin47.3%100.0%100.0%——
Research & Development190.29M155.51M114.36M158.9M8.99M
Selling, General & Admin899.94M199.88M63.91M216.46M4.48M
Operating Expenses2.11B355.38M515.65M375.36M13.48M
Depreciation & Amortization13.78M1.42M3.37M1.91M122.37K
EBITDA(2.06B)(51.23M)(344.25M)(373.45M)(13.35M)
EBITDA Margin-2337.4%478.9%-7674.2%——
Operating Income(2.07B)(366.08M)(511.16M)(375.36M)(13.48M)
Operating Margin-2353.1%3422.2%-11395.1%——
Interest Income21.33M4.95M7.3M54.64M1.09M
Interest Expense00101.85K00
Other Income / Expenses(260.73M)(607.09M)(954.53M)12.63M847.61K
Income Before Tax(2.33B)(973.17M)(1.47B)(362.73M)(12.63M)
Pre-Tax Margin-2649.3%9097.4%-32674.0%——
Income Tax Expense(494.81K)710.39K(1.26B)00
Net Income(2.33B)(2.51B)(1.47B)(162.26M)(6.61M)
Net Margin-2648.7%23438.9%-32674.0%——
EPS (Basic)(30.70)(30.38)(17.62)(4.46)(0.16)
EPS (Diluted)(30.68)(30.38)(17.62)(4.46)(0.16)
Weighted Avg Shares75.93M82.52M83.19M81.19M41.64M
Weighted Avg Shares (Diluted)75.96M82.52M83.23M81.19M41.64M

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.